Gabriella Camboni

Partner at Sofinnova Partners

Speaker

Gabriella Camboni is a Partner with Sofinnova Partners. She was co-founder and CEO of BiovelocITA, Italy’s first accelerator dedicated to biotech, and the model for the Sofinnova Biovelocita Strategy. As a Partner in the Sofinnova Biovelocita Strategy, Gabriella’s mission is to work with universities, research organizations and investors to create companies from the most groundbreaking scientific ideas. Earlier in her career, Gabriella was Chief Operations Officer of Ethical Oncology Science (EOS), a Sofinnova[1]backed startup devoted to translational research in oncology, which she co-founded with Silvano Spinelli in 2006. EOS was sold to Clovis in 2013. Prior to this, Gabriella held various positions in the pharmaceutical industry, including Head of Clinical Oncology at Boehringer Mannheim Italy, Head of Development at Novuspharma (a spin-off of Boehringer Mannheim that she co-founded, which is now CTI BioPharma), and Head of Medical Affairs Europe at Novartis Oncology. Gabriella obtained her MD from the University of Milan; she is a board-certified gastroenterologist and clinical pharmacologist. Gabriella was a member of the Board of Directors of Mission Therapeutics, a Sofinnova Partners portfolio company, until October 2023.